Lv1
46 积分 2021-03-11 加入
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
1天前
待确认
Ferritin aggregation cell engager for CAR T avidity engineering against refractory leukemias
4个月前
已完结
Defining Single Molecular Forces Required to Activate Integrin and Notch Signaling
5个月前
已完结
The tumor microenvironment’s role in the response to immune checkpoint blockade
10个月前
已完结
Ingestible optoelectronic capsules enable bidirectional communication with engineered microbes for controllable therapeutic interventions
1年前
已完结
皖公网安备34019202002308
